Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 1,500,000 shares, a decline of 15.3% from the December 31st total of 1,770,000 shares. Currently, 8.6% of the shares of the stock are sold short. Based on an average daily volume of 104,700 shares, the short-interest ratio is presently 14.3 days.
Institutional Investors Weigh In On Rapport Therapeutics
A number of large investors have recently modified their holdings of the company. Values First Advisors Inc. purchased a new stake in shares of Rapport Therapeutics during the third quarter worth approximately $31,000. BNP Paribas Financial Markets purchased a new position in shares of Rapport Therapeutics during the 3rd quarter worth approximately $34,000. New York State Common Retirement Fund acquired a new position in Rapport Therapeutics during the fourth quarter worth $62,000. JPMorgan Chase & Co. purchased a new position in Rapport Therapeutics in the third quarter worth $83,000. Finally, SG Americas Securities LLC acquired a new stake in Rapport Therapeutics in the third quarter valued at $101,000.
Rapport Therapeutics Trading Down 1.2 %
RAPP stock traded down $0.22 during midday trading on Wednesday, reaching $17.55. The stock had a trading volume of 65,928 shares, compared to its average volume of 102,101. The company's fifty day simple moving average is $17.58 and its 200 day simple moving average is $20.39. Rapport Therapeutics has a 52-week low of $12.09 and a 52-week high of $29.74.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.07. Research analysts expect that Rapport Therapeutics will post -3.65 earnings per share for the current fiscal year.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
